Uceris

Proteinuria, Asthma, Itching + 16 more
Treatment
20 Active Studies for Uceris

What is Uceris

BudesonideThe Generic name of this drug
Treatment SummaryBudesonide is a type of steroid used to treat inflammation of the lungs and intestines. It is used to treat asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was approved by the FDA in 1994 and is sold under brand names such as Pulmicort and Entocort.
Rhinocortis the brand name
image of different drug pills on a surface
Uceris Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rhinocort
Budesonide
1994
134

Effectiveness

How Uceris Affects PatientsBudesonide is a medication used to decrease inflammation in the respiratory and digestive systems. The amount of budesonide taken can vary greatly between patients and it is known to be a relatively safe drug. However, patients should be aware of the risk of increased cortisol levels in the body and suppressed adrenal glands when taking this drug.
How Uceris works in the bodyCorticosteroids reduce inflammation by stopping blood vessels from widening and white blood cells from moving to the inflamed area. They also change how genes are expressed, which affects how cells behave. Corticosteroids reduce the body's ability to create inflammation-causing molecules and increase the production of anti-inflammatory molecules. At lower doses, corticosteroids reduce inflammation, and at higher doses, they suppress the immune system. When taken for a long time, corticosteroids can also raise sodium levels and lower potassium levels in the body.

When to interrupt dosage

The quantity of Uceris is contingent upon the diagnosed condition, including Vasomotor Rhinitis, Crohn's Disease and Chronic Obstructive Pulmonary Disease (COPD). The amount of dosage varies, as per the administration technique (e.g. Enema; Kit; Tablet - Rectal or Respiratory (inhalation)) detailed in the below table.
Condition
Dosage
Administration
Asthma
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Chronic Obstructive Pulmonary Disease
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Acute Coryza
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Ulcerative Colitis
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Crohn's Disease
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Eosinophilic Esophagitis
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Nasal Congestion
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Hypersensitivity
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
IGA Glomerulonephritis
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Itching
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Proteinuria
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Skin Diseases
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
maintenance therapy
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Colitis, Collagenous
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Rhinitis, Vasomotor
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Nasal Polyps
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Sinusitis
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Crohn Disease
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral
Crohn Disease
, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation
Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Suspension, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Rectal, Aerosol, foam - Rectal, Aerosol, foam, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release, Capsule, coated pellets - Oral, Capsule, coated pellets, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Aerosol, metered - Nasal, Capsule, delayed release - Oral, Capsule, delayed release, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral

Warnings

Uceris Contraindications
Condition
Risk Level
Notes
Asthma
Do Not Combine
Severe Hepatic Impairment
Do Not Combine
Status Asthmaticus
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Budesonide may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Budesonide may interact with Pulse Frequency
There are 20 known major drug interactions with Uceris.
Common Uceris Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Budesonide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Budesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept.
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Budesonide.
Abetimus
Major
The risk or severity of adverse effects can be increased when Budesonide is combined with Abetimus.
Uceris Toxicity & Overdose RiskAcute overdose of corticosteroids is not common, however taking too much for too long can lead to an overproduction of corticosteroids and damage to the adrenal glands. In the case of overdose, the amount of corticosteroids taken should be reduced. A 200mg oral dose is deadly for female mice, and 400mg for male mice.

Uceris Novel Uses: Which Conditions Have a Clinical Trial Featuring Uceris?

516 active studies are presently examining the potential of Uceris to combat Chronic Obstructive Pulmonary Disease (COPD), Ulcerative Colitis and Allergic Reactions.
Condition
Clinical Trials
Trial Phases
Asthma
92 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3
Itching
2 Actively Recruiting
Phase 3, Not Applicable
Chronic Obstructive Pulmonary Disease
76 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4
Proteinuria
5 Actively Recruiting
Phase 2, Phase 3, Phase 4, Phase 1
IGA Glomerulonephritis
0 Actively Recruiting
Ulcerative Colitis
14 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1
Sinusitis
0 Actively Recruiting
Crohn's Disease
54 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Hypersensitivity
1 Actively Recruiting
Phase 4
Colitis, Collagenous
0 Actively Recruiting
Skin Diseases
0 Actively Recruiting
maintenance therapy
0 Actively Recruiting
Rhinitis, Vasomotor
0 Actively Recruiting
Eosinophilic Esophagitis
0 Actively Recruiting
Acute Coryza
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Nasal Polyps
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Nasal Congestion
0 Actively Recruiting

Uceris Reviews: What are patients saying about Uceris?

5Patient Review
7/1/2014
Uceris for Ulcerated Colon
I was on Balsalaszide and it wasn't helping me, so my doctor put me on Uceris. The results were amazing! I went from four bloody diarrhea stools to just one within a day, and now my stools are pretty normal. I'm very happy with this treatment.
5Patient Review
6/11/2018
Uceris for Ulcerated Colon
After a few weeks, my face became puffy and I had an increased heart rate.
4.3Patient Review
8/19/2014
Uceris for Ulcerated Colon
Overall, this treatment has been great for my colitis. I'm glad that insurance covers it because it's really expensive. The constant urination is a bit annoying, but it's better than going to the bathroom every time I eat something.
4Patient Review
11/24/2013
Uceris for Ulcerated Colon
3Patient Review
5/16/2014
Uceris for Ulcerated Colon
This has been a literal life-saver for my son who was diagnosed with Refractory Celiac Disease and Lymphocitic Colitis. Many other medications have failed where this one succeeded in reducing pain, frequency of bathroom trips, and ultimately allowed him to return to school!
1.7Patient Review
4/21/2016
Uceris for Ulcerated Colon
Uceris did not help me manage my colitis flare-up as advertised. If anything, it made the symptoms worse. I stopped taking it as soon as possible and Prednisone provided relief almost immediately.
1Patient Review
7/10/2018
Uceris for Ulcerated Colon
I had a lot of negative side effects from this medication, including pain, loss of appetite, and more trips to the bathroom with blood in my stool. I'm glad it works for some people, but it definitely wasn't the right fit for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about uceris

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Uceris weaken your immune system?

"If you take UCERIS tablets, it may weaken your immune system. This means that you are more likely to get infections. To avoid getting sick, stay away from people who have contagious diseases like chickenpox or measles."

Answered by AI

Is Uceris a steroid?

"Budesonide is a medication used to help get active, mild to moderate ulcerative colitis under control."

Answered by AI

What are the side effects of Uceris?

"The following are some possible side effects: headache, dizziness, indigestion, nausea, vomiting, stomach pain, bloating, gas, constipation, feeling tired, back pain, joint pain, painful urination, cold symptoms such as stuffy nose, sneezing, sore throat, or pain anywhere in your body."

Answered by AI

How long does it take for Uceris to work?

"The second, more bothersome side effect, was fatigue.

It took about two weeks for the medication to take effect and my diarrhea to stop completely. I had two side effects: swelling in both ankles that lasted for a few days, and fatigue, which was more bothersome."

Answered by AI

Clinical Trials for Uceris

Image of Johns Hopkins University School of Medicine in Baltimore, United States.

N-Acetylglucosamine for Crohn's Disease

13 - 80
All Sexes
Baltimore, MD
This study is a clinical trial of oral N-acetylglucosamine (GlcNAc) in patients with Crohn's disease (CD). This study includes two study groups divided by gene variation in a transporter protein that regulates manganese levels. This genetic variant increases the risk of Crohn's disease (especially involving the ileum) and is carried by approximately 10% of individuals with Crohn's disease. This genetic variant lowers manganese levels, and manganese is important in a cellular process called glycosylation, therefore, glycosylation is changed. Glycosylation in the gut controls the barrier function, interactions with the bugs in the gut, and immune function - all important in Crohn's disease. In this study, the investigators will test if this problem with glycosylation can be targeted by giving GlcNAc. GlcNAc is a key ingredient for glycosylation, and it is currently marketed as a dietary supplement in the United States.
Phase 2
Waitlist Available
Johns Hopkins University School of MedicineJoanna Melia, MD
Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Uceris clinical trials? We made a collection of clinical trials featuring Uceris, we think they might fit your search criteria.Go to Trials
Have you considered Uceris clinical trials? We made a collection of clinical trials featuring Uceris, we think they might fit your search criteria.Go to Trials
Image of Precision Clinical Research-Site Number: 8400059 in Coral Springs, United States.

Duvakitug for Crohn's Disease

16 - 80
All Sexes
Coral Springs, FL
This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-week Pivotal Maintenance Sub-Study * 240-week Open-Label Extension (OLE) Sub-Study * 45-day Follow-Up visit Note: For the participants who do not enroll into OLE Sub-Study, the duration will be up to 46 weeks, including the 40-week maintenance period and a 45-day follow-up visit. The treatment duration may be up to 280 weeks including: * 40 weeks in the Pivotal Maintenance Sub-Study * 240 weeks in OLE Sub-Study The total number of on-site visits will be up to 43: - 21 visits in the Pivotal Maintenance Sub-Study - 22 visits in the OLE Sub-Study
Phase 3
Recruiting
Precision Clinical Research-Site Number: 8400059 (+2 Sites)Sanofi
Image of Precision Clinical Research-Site Number: 8400059 in Coral Springs, United States.

Duvakitug for Crohn's Disease

16 - 80
All Sexes
Coral Springs, FL
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 weeks with: * Up to 5-week Screening Period. * 12-week Sub-Study 1 (Single Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction). * 12-week Sub-Study 3 (Extended Induction for non-responders). * 6 weeks (45 days) follow-up period for participants who do not enroll into the Pivotal Maintenance Study (EFC18327). The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled study visits for participants who continue to the Pivotal Maintenance Study (EFC18327) will be up to 8 (Sub-Study 1 and Sub-Study 2) and up to 15 for participants who enroll in Sub-Study 3.
Phase 3
Recruiting
Precision Clinical Research-Site Number: 8400059 (+28 Sites)Sanofi
Image of Victoria Hospital - London Health Sciences Centre in London, Canada.

Vitamin D for Inflammatory Bowel Disease

18 - 85
All Sexes
London, Canada
The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period? 2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients? 3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period? 4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period? 5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients? 6. Is 2,000 IU/Day an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients? Participants will: * Take 2000 IU of Vitamin D every day for the next 12 months * Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up
Phase 1
Waitlist Available
Victoria Hospital - London Health Sciences CentreTerry Ponich, MD
Image of UMASS medical center in Worcester, United States.

Cranberry for Crohn's Disease

18 - 65
All Sexes
Worcester, MA
This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research suggests that cranberry compounds may help support beneficial gut bacteria. In this study, adults with Crohn's disease will be randomly assigned to one of two groups: one group will receive a cranberry supplement to take once daily for 10 weeks, and the other group will receive a placebo (a supplement with no active ingredients). All participants will be asked to complete online questionnaires and collect samples of their blood, urine, and stool at four time points over a total of 15 weeks. These samples will help researchers understand how the cranberry supplement affects the gut microbiome, inflammation, and overall health. Participation is voluntary, and participants can withdraw from the study at any time. The results of this study may help identify new diet-based approaches to improve gut health in individuals with Crohn's disease.
Phase < 1
Recruiting
UMASS medical centerAna Maldonado-Contreras, PhD
Have you considered Uceris clinical trials? We made a collection of clinical trials featuring Uceris, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security